See related Janumet information |
|
Manufacturer |
MSD |
Distributor |
Zuellig |
Contents |
Per 50/500 mg tab Sitagliptin phosphate 50 mg, metformin HCl 500 mg. Per 50/1,000 mg tab Sitagliptin phosphate 50 mg, metformin HCl 1,000 mg |
Indications |
As initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. As adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or patients already receiving combination sitagliptin & metformin. May also be used in combination w/ a sulfonylurea, PPARγ agonist (eg thiazolidinedione) or insulin.
Click to view Janumet detailed prescribing infomation |
Dosage |
Individualized dosage. Initially 50 mg sitagliptin/500 mg metformin HCl bid, may be titrated up to 50 mg sitagliptin/1,000 mg metformin HCl bid. Max daily dose: Sitagliptin 100 mg. Patients inadequately controlled on metformin monotherapy Usual starting dose: Sitagliptin 50 mg bid, plus the dose of metformin already being taken. Patients inadequately controlled on sitagliptin monotherapy Usual starting dose: 50 mg sitagliptin/500 mg metformin HCl bid, may be titrated up to 50 mg sitagliptin/1,000 mg metformin HCl bid. Switching from co-administration of sitagliptin & metformin May be initiated at the dose of sitagliptin & metformin already being taken. Patients inadequately controlled on dual combination therapy w/ any 2 of these agents: sitagliptin, metformin or a sulfonylurea, or a PPARγ agonist, or insulin Usual starting dose: 50 mg sitagliptin bid. Determine dose of metformin based on glycemic control level & current metformin dose.
Click to view Janumet detailed prescribing infomation |
Overdosage |
View Janumet overdosage for action to be taken in the event of an overdose. |
Administration |
Should be taken with food |
Contraindications |
Renal disease or dysfunction, acute or chronic metabolic acidosis including diabetic ketoacidosis w/ or w/o coma. Intravascular administration of iodinated contrast materials (discontinue Janumet temporarily).
Click to view Janumet detailed prescribing infomation |
Special Precautions |
Not for use in type 1 DM. Monitor renal function & for signs/symptoms of pancreatitis. Hypoglycemia in combination w/ a sulfonylurea or insulin. Risk of lactic acidosis due to metformin content. Hypoxic states, surgery, impaired hepatic function, decreased vit B12 levels. Avoid excessive alcohol intake. Loss of glycemic control. Pregnancy & lactation. Childn <18 yr. Elderly.
Click to view Janumet detailed prescribing infomation |
Adverse Drug Reactions |
Diarrhea, nausea, dyspepsia, flatulence, vomiting, headache, hypoglycemia, abdominal pain.
View ADR Monitoring Form |
Side Effects |
View Janumet side effects |
Drug Interactions |
Metformin: Furosemide, nifedipine, cationic drugs (eg amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin), oral cimetidine. Thiazides & other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca antagonists, INH.
View more drug interactions with Janumet |
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
Storage |
View Janumet storage conditions for details to ensure optimal shelf-life. |
Description |
View Janumet description for details of the chemical structure and excipients (inactive components). |
Mechanism of Action |
View Janumet mechanism of action for pharmacodynamics and pharmacokinetics details. |
Presentation/Packing |
Form |
Packing |
Photo |
Janumet 50/500 mg tablet |
Janumet 28's |
 |
|
Janumet 50/1,000 mg tablet |
Janumet 28's |
 |
|
|
Manufacturer: |
MSD |
Distributor: |
Zuellig
|
|
|
|